VectivBio Holding, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an
Homburger acted as counsel to Swarovski International Holding in connection with the extension of its revolving credit facility, arranged by, amongst others, UBS Switzerland AG and Credit Suisse (Switzerland). Homburger advised Swarovski International Holding and
Valaris Limited and its wholly-owned subsidiary, Valaris Finance Company, closed the private placement of USD 700 million in aggregate principal amount of 8.375% senior secured second lien notes due 2030 and a senior secured first lien five-year credit
Homburger and Baker McKenzie have acted as advisors in connection with Comet Holding‘s new CHF 60 million multicurrency revolving credit facility agreement. Comet is a globally leading Swiss technology company in the plasma control and
Today, VAT Group has signed a syndicated term and multicurrency revolving credit facilities agreement with a syndicate of eleven banks, led by UBS Switzerland, to replace its current agreements that are due to expire in 2023.
Homburger has acted as counsel to UBS Switzerland as mandated lead arranger, agent, security agent and original lender in connection with the financing of the acquisition of Studer Cables’s parent company HC Holding Epsilon
VectivBio Holding, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has announced the pricing of a USD 125 m underwritten offering of ordinary shares. The underwritten offering consists of 16,700,000 ordinary shares at
Homburger has acted as counsel to Dätwyler Holding and Datwyler Parco Holdings in connection with a Swiss law governed USD 175 m credit facility arranged by UBS Switzerland for the purpose of refinancing certain indebtedness
VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, has entered into a loan agreement with Kreos Capital, a global growth lender to life sciences and healthcare companies, granting VectivBio
Homburger advises Roche Holding on the financing of the repurchase of the Novartis stake in Roche Holding On November 3, 2021, Roche Holding, as borrower entered into a CHF 9,814 billion and USD 10 billion bridge facility agreement with
